ERIS Lifescience

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,340.90",
    "chg": 4.8,
    "chgp": "0.36%",
    "dir": 1,
    "prev_price": "1,336.10",
    "mcapval": "18,311.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "Mar 27",
    "curr_time": "",
    "bse_nse_vol": "1.19 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 27, 2026",
    "traded_date_str": "2026 03 27",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-growing-price-pressure-3918446",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_valuationdot_3918446.png",
        "date": "2026-03-27 08:01:11",
        "description": "ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3917849",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_mojoScore_3917849.png",
        "date": "2026-03-26 10:10:26",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-changing-market-sentiment-3892663",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_valuationdot_3892663.png",
        "date": "2026-03-16 08:01:17",
        "description": "ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player in a new light for investors seeking value within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3892082",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_mojoScore_3892082.png",
        "date": "2026-03-15 10:10:23",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3881805",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_valuationdot_3881805.png",
        "date": "2026-03-10 08:01:15",
        "description": "ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3868928",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_mojoScore_3868928.png",
        "date": "2026-03-04 10:10:34",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Declines 5.13%: Margin Pressures and Valuation Shift Weigh on Stock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-declines-513-margin-pressures-and-valuation-shift-weigh-on-stock-3849535",
        "imagepath": "",
        "date": "2026-02-21 12:03:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Flat quarterly performance reported amid margin pressures</p>\n                    <p><strong>16 Feb:</strong> Technical downgrade to Sell amid bearish momentum</p>\n                    <p><strong>20 Feb:</strong> Valuation grade shifts from expensive to fair</p>\n                    <p><strong>20 Feb:</strong> Week closes at Rs.1,342.10 (-5.13%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,414.65</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,342.10</div><div..."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3849287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_mojoScore_3849287.png",
        "date": "2026-02-21 10:10:31",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-changing-market-sentiment-3847668",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_valuationdot_3847668.png",
        "date": "2026-02-20 08:01:17",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 305,
    "sid": "1002771",
    "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "details": "Eris Lifesciences Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Eris Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "05-Dec-2019"
    },
    {
      "details": "Eris Lifesciences Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Eris Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "03-Dec-2019"
    },
    {
      "details": "Eris Lifesciences Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Eris Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "28-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>735%</strong> dividend, ex-date: 13 Feb 25",
          "dt": "2025-02-13",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure

2026-03-27 08:01:11

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-03-26 10:10:26

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-03-16 08:01:17

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player in a new light for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-03-15 10:10:23

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-03-10 08:01:15

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-03-04 10:10:34

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

ERIS Lifesciences Declines 5.13%: Margin Pressures and Valuation Shift Weigh on Stock

2026-02-21 12:03:56

Key Events This Week

16 Feb: Flat quarterly performance reported amid margin pressures

16 Feb: Technical downgrade to Sell amid bearish momentum

20 Feb: Valuation grade shifts from expensive to fair

20 Feb: Week closes at Rs.1,342.10 (-5.13%)

Week Open

Rs.1,414.65

Week Close

Rs.1,342.10

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-02-21 10:10:31

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-20 08:01:17

ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News